| Li, Michael KW |
| Recruiting | N/A | 55 | US | Contingency Management | University of California, Los Angeles, National Institute on Drug Abuse (NIDA) | Substance-Related Disorders, HIV | 03/25 | 03/26 | | |
| Recruiting | N/A | 250 | US | PrEP navigation + text messaging, Standard of Care, Contingency Management | Friends Research Institute, Inc., Weill Medical College of Cornell University, University of California, Los Angeles, Emory University | Substance Use Disorders, HIV | 06/27 | 06/27 | | |
| Trivedi, Madhukar |
| Not yet recruiting | 4 | 2726 | Canada, US | Cariprazine, Vraylar, Aripiprazole/Escitalopram combination, Abilify/ Lexapro, Quetiapine, Seroquel, Lurasidone, Latuda | Massachusetts General Hospital, Patient-Centered Outcomes Research Institute | Bipolar I Disorder, Depression | 02/30 | 02/30 | | |
NCT04592809: Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents |
|
|
| Recruiting | 3 | 264 | US | Ketamine Hydrochloride, Ketalar, Midazolam Hydrochloride, Versed | University of Texas Southwestern Medical Center, National Institute of Mental Health (NIMH) | Suicide, Attempted, Suicide and Depression, Suicide Threat | 05/26 | 11/26 | | |
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD |
|
|
| Recruiting | 3 | 568 | Europe, Canada, US, RoW | Psilocybin, COMP360 | COMPASS Pathways | Treatment Resistant Depression | 03/25 | 05/25 | | |
| Terminated | 2 | 18 | US | Buprenorphine injection (BUP-Inj), SublocadeTM, Indivior, Placebo injection, Placebo injection (PBO-Inj) | Madhukar H. Trivedi, MD | Methamphetamine-dependence | 10/23 | 11/23 | | |
CURB-2, NCT05262270: Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder |
|
|
| Recruiting | 2 | 426 | US | Extended-Release Naltrexone, XR-NTX, Extended Release Buprenorphine, XR-BUP, Placebo (PLB) Injectable matched to XR-NTX, Injectable matching (to XR-NTX) placebo, Placebo (PLB) Injectable matched to XR-BUP, Injectable matching (to XR-BUP) placebo | University of Texas Southwestern Medical Center, National Institute on Drug Abuse (NIDA) | Cocaine Use Disorder | 03/25 | 09/26 | | |
NCT02697487: UTSW Depression Cohort: A Longitudinal Study of Depression |
|
|
| Completed | N/A | 447 | US | No treatment | University of Texas Southwestern Medical Center | Depression, Other Diagnoses, Comorbidities, and Complications | 03/18 | 03/18 | | |
I-DREM, NCT05124119: Strategies to Enhance Recruitment and Retention of Black Individuals Into Clinical Trials for Substance Use Disorders |
|
|
| Completed | N/A | 65 | US | | University of Texas Southwestern Medical Center, National Institute on Drug Abuse (NIDA) | Substance Use Disorders | 12/22 | 07/24 | | |
MBC4OUD, NCT04059016: Innovatively Increasing PCP Prescribing of Buprenorphine: Measurement Based Care and Integrated Electronic Solution |
|
|
| Completed | N/A | 75 | US | MBC4OUD | University of Texas Southwestern Medical Center, National Institute on Drug Abuse (NIDA) | Opioid Abuse and Addiction | 05/24 | 05/24 | | |
NCT04783506: Characterizing Inflammatory Profiles and Suicidal Behavior in Adolescents |
|
|
| Recruiting | N/A | 225 | US | Observational Study | University of Texas Southwestern Medical Center, American Foundation for Suicide Prevention | Suicide and Depression | 03/25 | 05/25 | | |
| Completed | N/A | 129 | US | rTMS, Repetitive Transcranial Magnetic Stimulation, TMS, Sham (Placebo), Sham Repetitive Transcranial Magnetic Stimulation | Medical University of South Carolina, National Institute on Drug Abuse (NIDA) | Cocaine Use Disorder, Methamphetamine Abuse, Cocaine Dependence, Methamphetamine Dependence, Stimulant Use, Stimulant Abuse, Methamphetamine Use Disorder, Cocaine Abuse, Stimulant Use Disorder | 05/24 | 08/24 | | |
| Active, not recruiting | N/A | 65 | US | Behavioral Activation Teletherapy | University of Texas Southwestern Medical Center | Depression, Depressive Disorder, Depressive Symptoms, Depressive Episode | 10/24 | 05/25 | | |
| Recruiting | N/A | 5000 | US | | University of Texas Southwestern Medical Center | Depression, Suicide, Suicidal Ideation, Suicide, Attempted, Depressive Disorder, Depressive Symptoms, Depressive Episode, Depression and Suicide, Depression, Teen, Depression, Anxiety | 08/32 | 09/32 | | |
| Recruiting | N/A | 60 | US | RMIST | University of Texas Southwestern Medical Center, National Institute on Drug Abuse (NIDA) | Opioid Use Disorder | 03/25 | 03/25 | | |
NCT02919280: Dallas 2K: A Natural History Study of Depression |
|
|
| Recruiting | N/A | 2000 | US | Observational Study | University of Texas Southwestern Medical Center, The Hersh Foundation | Depression, Depression, Bipolar | 09/26 | 09/26 | | |
| Recruiting | N/A | 1500 | US | | University of Texas Southwestern Medical Center | Risk Assessment, Resilience, Psychological, Depression, Mood Disorders, Anxiety Disorders | 12/31 | 12/32 | | |
| Recruiting | N/A | 1500 | US | | University of Texas Southwestern Medical Center | Stimulant Use, Stimulant-Related Disorder, Healthy | 11/33 | 11/33 | | |
SABR, NCT06002204: Studying the Health of Asians to Advance Knowledge, Treatments, and Interventions for Depression |
|
|
| Recruiting | N/A | 6000 | US | Observational Study | University of Texas Southwestern Medical Center | Depression, Treatment Resistant Depression, Mood Disorders, Bipolar Disorder, Mental Disorders, Bipolar and Related Disorders | 02/34 | 02/35 | | |
| Gandhi, Monica |
PUMA, NCT03935464: Point-of-care Urine Monitoring of Adherence: Testing a Real-Time Urine Assay of Tenofovir in PrEP |
|
|
| Completed | N/A | 100 | RoW | PUMA | University of California, San Francisco, Kenya Medical Research Institute, University of Washington, National Institute of Allergy and Infectious Diseases (NIAID) | Risk Reduction | 03/24 | 03/24 | | |
UTRA, NCT05333679: Urine Tenofovir Point-of-care Test to Identify Patients in Need of ART Adherence Support ( Study) |
|
|
| Active, not recruiting | N/A | 200 | RoW | UTRA, UTRA feedback | University of California, San Francisco, University of Cape Town, University of Stellenbosch, National Institute of Allergy and Infectious Diseases (NIAID) | Risk Reduction | 06/25 | 06/25 | | |
ROVING-PUMA, NCT06423612: Randomized Trial to Optimize Virologic Suppression Rates Using a Point-of-Care Urine Monitoring Assay (ROVING PUMA) |
|
|
| Not yet recruiting | N/A | 500 | RoW | POC urine assay informed enhanced ART adherence counselling for viral suppression | University of California, San Francisco, Desmond Tutu HIV Foundation, University of Cape Town, National Institute of Allergy and Infectious Diseases (NIAID) | ART Adherence | 11/26 | 11/26 | | |
| Shoptaw, Steven |
NCT04614584: Mirtazapine and Methamphetamine Drug-drug Interaction Study |
|
|
| Completed | 1 | 15 | US | Mirtazapine, Methamphetamine | San Francisco Department of Public Health, University of California, Los Angeles | Methamphetamine Use Disorder, Drug Interaction, Cardiovascular Abnormalities | 05/24 | 05/24 | | |
| Enrolling by invitation | N/A | 200 | US | Opioid Addiction Recovery Support Software Platform, OARS | Q2i, LLC, University of California, Los Angeles, National Institute on Drug Abuse (NIDA) | Opioid-use Disorder | 05/23 | 08/23 | | |
NCT04801758: Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 704/HPTN 085 AMP Study |
|
|
| Completed | N/A | 18 | RoW | Analytical Treatment Interruption | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | HIV Infection | 07/24 | 07/24 | | |
| Clark, Jesse L |
NCT06233799: Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder |
|
|
| Recruiting | 3 | 360 | US | extended-release naltrexone (XR-NTX), Vivitrol, extended release bupropion (BUP-XL) tablets (BUP-XL), Wellbutrin, iPLB, Placebo injections, oPLB, Placebo tablets | National Institute on Drug Abuse (NIDA) | Methamphetamine-dependence, Methamphetamine Abuse | 10/26 | 04/27 | | |
| Terminated | 2 | 18 | US | Buprenorphine injection (BUP-Inj), SublocadeTM, Indivior, Placebo injection, Placebo injection (PBO-Inj) | Madhukar H. Trivedi, MD | Methamphetamine-dependence | 10/23 | 11/23 | | |
CURB-2, NCT05262270: Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder |
|
|
| Recruiting | 2 | 426 | US | Extended-Release Naltrexone, XR-NTX, Extended Release Buprenorphine, XR-BUP, Placebo (PLB) Injectable matched to XR-NTX, Injectable matching (to XR-NTX) placebo, Placebo (PLB) Injectable matched to XR-BUP, Injectable matching (to XR-BUP) placebo | University of Texas Southwestern Medical Center, National Institute on Drug Abuse (NIDA) | Cocaine Use Disorder | 03/25 | 09/26 | | |
NCT05217641: A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants |
|
|
| Active, not recruiting | 1 | 108 | US | BG505 MD39.3 mRNA, BG505 MD39.3 gp151 mRNA, BG505 MD39.3 gp151 CD4KO mRNA | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services | HIV Infections | 07/23 | 06/27 | | |
NCT04614584: Mirtazapine and Methamphetamine Drug-drug Interaction Study |
|
|
| Completed | 1 | 15 | US | Mirtazapine, Methamphetamine | San Francisco Department of Public Health, University of California, Los Angeles | Methamphetamine Use Disorder, Drug Interaction, Cardiovascular Abnormalities | 05/24 | 05/24 | | |
| Completed | N/A | 555 | RoW | EPT | University of California, Los Angeles, Asociacion Civil Via Libre, University of California, San Francisco, Emory University | HIV-1-infection, Gonorrhea Male, Chlamydia, Partner Communication | 04/24 | 04/24 | | |
| Hendricks, Peter S |
NCT03912194: Early Withdrawal Exposure and Negative Affect Withdrawal (NAW) Regulation Training for Smoking Cessation |
|
|
| Recruiting | 3 | 400 | US | cognitive-behavioral withdrawal regulation strategies, relaxation strategies, early withdrawal exposure | University of Alabama at Birmingham | Tobacco Dependence | 03/26 | 06/26 | | |
| Recruiting | 3 | 240 | US | Psilocybin 25 mg, Psilocybine, Psilocibin, Indocybin, Inactive Placebo, Microcrystalline Cellulose (MCC), Placebo, Psilocybin 5 mg, Psilocybine, Psilocibin, Indocybin, Active Comparator, Psychosocial Support | Usona Institute, Worldwide Clinical Trials | Depressive Disorder, Major | 04/25 | 04/26 | | |
NCT02037126: Psilocybin-facilitated Treatment for Cocaine Use |
|
|
| Completed | 2 | 40 | US | Psilocybin, psychedelic compound, Diphenhydramine, Benadryl | University of Alabama at Birmingham | Cocaine-Related Disorders | 05/24 | 05/24 | | |
NCT05452772: 5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder |
|
|
| Recruiting | 2 | 66 | US | Psilocybin, Active Experimental Group, Niacin, Active Comparator Group | Johns Hopkins University, University of Alabama at Birmingham, New York University, Sheppard Pratt Health System, National Institute on Drug Abuse (NIDA) | Tobacco Use Disorder | 05/25 | 12/25 | | |
CURB-2, NCT05262270: Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder |
|
|
| Recruiting | 2 | 426 | US | Extended-Release Naltrexone, XR-NTX, Extended Release Buprenorphine, XR-BUP, Placebo (PLB) Injectable matched to XR-NTX, Injectable matching (to XR-NTX) placebo, Placebo (PLB) Injectable matched to XR-BUP, Injectable matching (to XR-BUP) placebo | University of Texas Southwestern Medical Center, National Institute on Drug Abuse (NIDA) | Cocaine Use Disorder | 03/25 | 09/26 | | |
| Recruiting | 1 | 60 | US | Psilocybin, Placebo | University of Alabama at Birmingham, Diamond Therapeutics Inc. | Demoralization | 12/24 | 12/24 | | |
NCT05068791: Psilocybin-facilitated Treatment for Chronic Pain |
|
|
| Recruiting | 1 | 30 | US | Psilocybin, Dextromethorphan | University of Alabama at Birmingham | Fibromyalgia, Primary | 12/24 | 01/25 | | |
| Hall, Timothy |
SURPASS-EARLY, NCT05433584: A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes |
|
|
| Active, not recruiting | 4 | 780 | Europe, Canada, US, RoW | Tirzepatide, LY3298176, Antihyperglycemic medication | Eli Lilly and Company | Type 2 Diabetes | 10/25 | 11/27 | | |
SURMOUNT-5, NCT05822830: A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities |
|
|
| Completed | 3 | 751 | US | Tirzepatide, LY3298176, Semaglutide | Eli Lilly and Company | Obesity, Overweight | 11/24 | 11/24 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
| Terminated | 2 | 18 | US | Buprenorphine injection (BUP-Inj), SublocadeTM, Indivior, Placebo injection, Placebo injection (PBO-Inj) | Madhukar H. Trivedi, MD | Methamphetamine-dependence | 10/23 | 11/23 | | |
| Blair, Cherie |
| Active, not recruiting | N/A | 30 | US | Contingency Management | University of California, Los Angeles | Methamphetamine-dependence, Rectal Gonorrhea, Rectal Chlamydia | 06/26 | 06/27 | | |
| Riley, Simone J |
| Terminated | 2 | 18 | US | Buprenorphine injection (BUP-Inj), SublocadeTM, Indivior, Placebo injection, Placebo injection (PBO-Inj) | Madhukar H. Trivedi, MD | Methamphetamine-dependence | 10/23 | 11/23 | | |
| Tavarez, Jasmin |
CURB-2, NCT05262270: Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder |
|
|
| Recruiting | 2 | 426 | US | Extended-Release Naltrexone, XR-NTX, Extended Release Buprenorphine, XR-BUP, Placebo (PLB) Injectable matched to XR-NTX, Injectable matching (to XR-NTX) placebo, Placebo (PLB) Injectable matched to XR-BUP, Injectable matching (to XR-BUP) placebo | University of Texas Southwestern Medical Center, National Institute on Drug Abuse (NIDA) | Cocaine Use Disorder | 03/25 | 09/26 | | |
